within Pharmacolibrary.Drugs.ATC.R;

model R05DA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 60 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Opium alkaloids with morphine comprise a combination of opium-derived alkaloids, predominantly morphine, used historically as antitussive (cough suppressant) agents. The combination acts primarily through opioid receptors, providing relief from severe cough. Given the potential for abuse and side effects, its use is now largely obsolete or restricted in many countries, replaced by safer alternatives. It is not widely approved for use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated based on typical oral morphine preparations in adults, as no specific population PK model or clinical study of pharmacokinetics for this fixed combination is available.</p><h4>References</h4><ol><li><p>Lugo, RA, &amp; Kern, SE (2002). Clinical pharmacokinetics of morphine. <i>Journal of pain &amp; palliative care pharmacotherapy</i> 16(4) 5–18. DOI:<a href=&quot;https://doi.org/10.1080/j354v16n04_02&quot;>10.1080/j354v16n04_02</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14635822/&quot;>https://pubmed.ncbi.nlm.nih.gov/14635822</a></p></li><li><p>Lugo, RA, &amp; Kern, SE (2004). The pharmacokinetics of oxycodone. <i>Journal of pain &amp; palliative care pharmacotherapy</i> 18(4) 17–30. DOI:<a href=&quot;https://doi.org/10.1300/j354v18n04_03&quot;>10.1300/j354v18n04_03</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15760805/&quot;>https://pubmed.ncbi.nlm.nih.gov/15760805</a></p></li><li><p>Christrup, LL (1997). Morphine metabolites. <i>Acta anaesthesiologica Scandinavica</i> 41(1 Pt 2) 116–122. DOI:<a href=&quot;https://doi.org/10.1111/j.1399-6576.1997.tb04625.x&quot;>10.1111/j.1399-6576.1997.tb04625.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9061094/&quot;>https://pubmed.ncbi.nlm.nih.gov/9061094</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R05DA05;
